Abbott Laboratories (NYSE:ABT) Bolsa

ABBOTT LABORATORIES

Abbott Laboratories

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Time magazine

Long Ideas

Tech

Media

Trading Ideas

AMZN

ASML

BABA

BYDDF

BYDDY

CMCSA

COIN

COUR

CRSP

DASH

DUOL

ENGIY

EQNR

ESLOY

GILD

GOOG

GOOGL

HYMTF

LRLCY

MELI

MSFT

NFLX

NTDOY

ONON

PLTR

PMRTY

SFTBF

SFTBY

UMGNF

UNVGY

TIME revela las 100 empresas más influyentes de 2025. Conoce las compañías en bolsa que lideran innovación y crecimiento este año.

Las empresas más influyentes de 2025 según TIME: ¿Cuáles están en bolsa?

Oct,15,,2019,Sunnyvale, - ,Ca, - ,Usa,-,Close

Earnings

News

Pre-Market Outlook

Markets

JBHT

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: ABT, TRV, JBHT, ASML y PGR.

5 acciones en el foco este miércoles: ABT, TRV, JBHT, ASML y PGR

IBKR

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este miércoles: ABT, NFLX, PG, IBKR y JNJ.

5 acciones en el foco este miércoles: ABT, NFLX, PG, IBKR y JNJ

Arcblock - United States dollar

ALTEROLA BIOTECH INC by Alterola Biotech, Inc.

Alterola Biotech Inc

AB&T Financial Corp Com

Abits Group Inc

ABOITIZ EQTY VNT UNSP/ADR by Aboitiz Equity Ventures, Inc.

Aboitiz Equity Ventures Inc

Wells Fargo analyst Lawrence Biegelsen maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Overweight and lowers the price target from $147 to $142.

Price Target

Analyst Ratings

Wells Fargo Maintains Overweight on Abbott Laboratories, Lowers Price Target to $142

Abbott Laboratories's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) short percent of float has fallen 5.83% since its last report. The company recently reported that it has 19.43 million shares sold short, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.72 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Abbott Laboratories Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752861629_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Abbott Laboratories has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Abbott Laboratories's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Abbott Laboratories's peer group average for short interest as a percentage of float is 4.29%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Abbott Laboratories's Recent Short Interest

WIIM

Abbott Laboratories shares are trading higher after Jefferies upgraded the stock from hold to buy and raised the price target from $143 to $145. The move may also reflect a rebound following Thursday's drop on weak guidance.

Raymond James analyst Jayson Bedford maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Outperform and lowers the price target from $142 to $141.

Raymond James Maintains Outperform on Abbott Laboratories, Lowers Price Target to $141

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected sales and profits in the second quarter, but dialed back earnings and growth projections for the <a href="https://www.benzinga.com/quote/ABT/earnings">rest of the year</a>.
The company reported second-quarter sales of $11.14 billion, beating the consensus of $11.07 billion. The U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management guidance of $1.23-$1.27.
"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline," said Robert B. Ford, chairman and chief executive officer, Abbott. "We see this momentum carrying into 2026."
Abbott narrowed full-year 2025 adjusted earnings guidance from $5.05-$5.25 per share to $5.10-$5.20 per share compared to the consensus of $5.16. The company expects organic sales growth of 7.5%-8.0% compared to prior guidance of 7.5%-8.5%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%. Abbott expected third-quarter 2025 adjusted earnings of $1.28-$1.32 per share, compared to the consensus of $1.34 per share.
Abbott shares dipped 8.5% to close at $120.51 on Thursday.
These analysts made changes to their price targets on Abbott following earnings announcement.
<ul class="wp-block-list">
<li>BTIG analyst Marie Thibault maintained Abbott Laboratories with a Buy and lowered the price target from $148 to $145.</li>
<li>Jefferies analyst Matthew Taylor upgraded Abbott from Hold to Buy and raised the price target from $143 to $145.</li>
<li>Mizuho analyst Anthony Petrone maintained Abbott with a Neutral and lowered the price target from $140 to $135.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/abt/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18090126/image-254-1024x589.png" alt="" class="wp-image-991534" style="width:624px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18090126/image-254-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18090126/image-254-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18090126/image-254-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18090126/image-254.png 1153w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46465973/top-2-defensive-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo via Shutterstock

These Analysts Revise Their Forecasts On Abbott Following Q2 Results

Mizuho analyst Anthony Petrone maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Neutral and lowers the price target from $140 to $135.

Mizuho Maintains Neutral on Abbott Laboratories, Lowers Price Target to $135

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Jefferies raised Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) price target from $143 to $145. Jefferies analyst Matthew Taylor upgraded the stock from Hold to Buy. Abbott shares closed at $120.51 on Thursday. S<a href="https://www.benzinga.com/quote/abt/analyst-ratings">ee how other analysts view this stock</a>.</li>
<li>Morgan Stanley cut the price target for The Progressive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PGR#NYSE">PGR</a>) from $280 to $275. Morgan Stanley analyst Bob Huang maintained an Equal-Weight rating. Progressive shares closed at $247.27 on Thursday. <a href="https://www.benzinga.com/quote/pgr/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Snap-on Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) price target from $265 to $285. B of A Securities analyst Elizabeth Suzuki maintained an Underperform rating. Snap-on shares closed at $337.80 on Thursday. <a href="https://www.benzinga.com/quote/sna/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted the price target for Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) from $227 to $230. Baird analyst Andrew Wittmann maintained a Neutral rating. Cintas shares closed at $221.92 on Thursday. <a href="https://www.benzinga.com/quote/ctas/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley boosted the price target for Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) from $1,450 to $1,500. Morgan Stanley analyst Benjamin Swinburne maintained an Overweight rating. Netflix shares closed at $1,274.17 on Thursday. <a href="https://www.benzinga.com/quote/nflx/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keefe, Bruyette &amp; Woods raised Webster Financial Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) price target from $65 to $68. Keefe, Bruyette &amp; Woods analyst Christopher Mcgratty maintained an Outperform rating. Webster Financial shares settled at $60.05 on Thursday. <a href="https://www.benzinga.com/quote/wbs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group increased Amphenol Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APH#NYSE">APH</a>) price target from $105 to $110. Evercore ISI Group analyst Amit Daryanani maintained an Outperform rating. Amphenol shares closed at $101.96 on Thursday. <a href="https://www.benzinga.com/quote/aph/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $515 to $585. B of A Securities analyst Brad Sills maintained a Buy rating. Microsoft shares closed at $511.70 on Thursday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital raised the price target for International Business Machines Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) from $260 to $300. BMO Capital analyst Keith Bachman maintained a Market Perform rating. IBM shares settled at $282.00 on Thursday. <a href="https://www.benzinga.com/quote/ibm/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities increased Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) price target from $200 to $210. B of A Securities analyst Justin Post maintained a Buy rating. Alphabet shares closed at $183.58 on Thursday. <a href="https://www.benzinga.com/quote/googl/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying MSFT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="584" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18080328/image-252-1024x584.png" alt="" class="wp-image-991416" style="width:547px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18080328/image-252-1024x584.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18080328/image-252-300x171.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18080328/image-252-768x438.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/18080328/image-252.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46465973/top-2-defensive-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Defensive Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>
Photo via Shutterstock

CTAS

Microsoft To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday

Jefferies analyst Matthew Taylor upgrades Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) from Hold to Buy and raises the price target from $143 to $145.

Upgrades

Jefferies Upgrades Abbott Laboratories to Buy, Raises Price Target to $145

BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and lowers the price target from $148 to $145.

BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $145

Looking into the current session, Abbott Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) shares are trading at $121.11, after a 8.07% drop. Over the past month, the stock fell by 8.93%, but over the past year, it actually went up by 18.71%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1752775227_0.png" alt="Past Year Chart" />

<h3>How Does Abbott Laboratories P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Abbott Laboratories has a lower P/E than the aggregate P/E of 53.67 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1752775227_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

P/E Ratio Insights for Abbott Laboratories

U.S. equities climbed on Thursday, with the S&amp;P 500 briefly testing a record high 6,300 level at midday in New York, bolstered by strong earnings and upbeat retail sales data that <a href="https://www.benzinga.com/markets">reinforced investor risk appetite</a>.
The Nasdaq 100 rose 0.9% to a fresh record above 23,000, while the Dow Jones Industrial Average gained 0.4% to 44,400. Small-cap stocks continued to outperform, with the Russell 2000 advancing 1.3%.
Retail sales rebounded in June, rising 0.6% month-over-month after a revised 0.9% drop in May, far exceeding consensus expectations of a 0.1% gain. Meanwhile, initial jobless claims fell to 221,000, the lowest since April, suggesting ongoing resilience in the labor market.
Investor nerves eased after President Donald Trump denied reports suggesting he was considering the removal of Federal Reserve Chair Jerome Powell.
Tech-led sector gains, with the combined market capitalization of the so-called Magnificent Seven stocks climbing to $18.4 trillion.
Bond market jitters persisted as 30-year Treasury yields touched 5%, though equity markets largely shrugged off the move.
The U.S. dollar strengthened 0.4%. Commodities rallied, driven by a 1.6% rise in oil prices to above $67 per barrel, while platinum hit its highest level since August 2014.
In cryptocurrencies, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) held steady around $118,870. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) rose 1.3%, extending its winning streak to nine gains in the last 10 sessions.
<h2 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,253.82</td>
<td>1.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,104.30</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,297.76</td>
<td>0.5%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,475.55</td>
<td>0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:10 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.5% to $576.76.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.5% to $444.72.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 0.8% to $561.85.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 1.2% to $223.68.</li>
<li>The&nbsp;Technology&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, up 0.9%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.8%.</li>
</ul>
<h2 class="wp-block-heading">Thursday&#8217;s Stock Movers</h2>
PepsiCo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) shares climbed over 6% after the beverage giant reported quarterly earnings and revenue that topped analyst expectations.
United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) rose 5.7% earlier in the day, despite issuing a muted full-year earnings outlook. The company noted that its financial trajectory has become more predictable compared to the volatile first half of the year.
Earnings-driven stock moves included:
<ul class="wp-block-list">
<li>Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>), down 8%</li>
<li>GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>), down 2.2%</li>
<li>Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), down 11%</li>
<li>Cintas Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>), up 2.7%</li>
<li>U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>), down 1.4%</li>
<li>The Travelers Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>), up 2.8%</li>
<li>Citizens Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>), up 3.5%</li>
</ul>
Lucid Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) soared more than 40% after unveiling a partnership with Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) and autonomous vehicle startup Nuro to launch a robotaxi program. The initiative will deploy 20,000 autonomous vehicles, backed by a $300 million investment from Uber.
Netflix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is scheduled to report its earnings after the closing bell.
Read Now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/author/piero-cingari">Defense Stocks Head Into Earnings At Record Highs — Is The Boom Just Beginning? </a></li>
</ul>
Photo: Shutterstock

Equities

Government

Large Cap

Regulations

Broad U.S. Equity ETFs

ETFs

$BTC

$ETH

SPDR Dow Jones Industrial Average ETF Trust

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

LCID

UBER

Nasdaq 100 Sets New Records, Small Caps Outperform: What's Moving Markets Thursday?

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) reported better-than-expected sales and profits in the second quarter, but the stock still plummeted nearly 10% after management dialed back earnings and growth projections for the rest of the year.
The company reported second-quarter sales of $11.14 billion, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $11.07 billion</a>.
Second-quarter sales increased 7.4% on a reported basis, 6.9% on an organic basis, or 7.5% when excluding COVID-19 testing-related sales.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/07/46468951/elevance-health-hit-by-medicaid-troubles-trims-outlook" rel="noreferrer noopener">Elevance Health Hit By Medicaid Troubles, Trims Outlook</a>
The U.S. MedTech giant reported adjusted earnings of $1.26, beating the consensus of $1.25, and within the management <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44838946/abbott-labs-clocks-q1-profit-beat-ceo-says-diversification-and-execution-enable-navigation-during-uncertainty" rel="noreferrer noopener">guidance of $1.23-$1.27</a>.
&#8220;Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly expanded our margin profiles, and continued to advance key programs through our new product pipeline,&#8221; said Robert B. Ford, chairman and chief executive officer, Abbott. &#8220;We see this momentum carrying into 2026.&#8221;
Medical Devices sales increased 13.4% on a reported basis and 12.2% on an organic basis to $5.37 billion.
Sales growth in the quarter was led by double-digit growth in Diabetes Care, Heart Failure, Structural Heart, and Electrophysiology.
Several products contributed to the performance, including FreeStyle Libre, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46463570/abbott-reports-second-quarter-2025-results" rel="noreferrer noopener">Navitor, TriClip, and AVEIR</a>.
In Diabetes Care, sales of continuous glucose monitors were $1.9 billion and grew 21.4% on a reported basis and 19.6% organically.&nbsp;
Worldwide Nutrition sales increased 2.9% (+3.4% on an organic basis) to $2.21 billion.
Growth in the quarter was led by Adult Nutrition, where global sales increased 6.1% (+6.6% on an organic basis), led by strong growth of Ensure and Glucerna.
Global Diagnostics sales decreased 1% (-1.4% on an organic basis) and increased 0.8% when excluding COVID-19 testing-related sales.
The year-over-year decline in COVID-19 testing-related sales and volume-based procurement programs in China impacted diagnostics sales growth.
COVID-19 testing-related sales were $55 million in the quarter, compared to $102 million a year ago.
Established Pharmaceuticals sales increased 6.9% (+7.7% on an organic basis) to $1.38 billion.
Abbott&#8217;s reported operating margin of 18.4%, with an adjusted operating margin of 22.9%, which reflects a 100 basis point increase.
<h2 class="wp-block-heading">Guidance</h2>
Abbott narrowed full-year 2025 adjusted earnings guidance from $5.05-$5.25 per share to $5.10-$5.20 per share compared to the consensus of $5.16.
The company expects organic sales growth of 7.5%-8.0% compared to prior guidance of 7.5%-8.5%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
Abbott forecasts an adjusted operating margin of approximately 23.5% of sales, down from prior guidance of 23.5%- 24.0%.
Abbott expected third-quarter 2025 adjusted earnings of $1.28-$1.32 per share, compared to the consensus of $1.34 per share.
During the earnings conference call, an Abbott executive addressed the impact of tariffs, reporting that the estimated headwind has been revised down to $200 million for the year, lower than previous estimates.&nbsp;
Price Action:&nbsp;ABT stock is trading lower by 8.00% to $121.21&nbsp;at last check Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46465321/novartis-trims-operating-income-outlook-after-strong-q2-performance-initiates-10-billion-stock-buyback" target="_blank" rel="noreferrer noopener">Novartis Trims Operating Income Outlook After Strong Q2 Performance, Initiates $10 Billion Stock Buyback</a></li>
</ul>
Photo via Shutterstock

Guidance

Health Care

Movers

General

Eased Tariff Impact Fails To Lift Abbott As Outlook Cut Disappoints Investors

During Conference Call, Abbott Exec Reportedly Says $200 Million Tariff Impact Is Down From Previous Estimates

U.S. stock futures were mostly lower this morning, with the Dow futures falling around 0.2% on Thursday.
Shares of Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) fell sharply in pre-market trading after the company issued third-quarter <a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/07/46447307/abbott-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">adjusted EPS guidance below estimates.</a>
Abbott posted adjusted earnings of $1.26 per share, beating market estimates of $1.25 per share. The company's sales came in at $11.142 billion versus expectations of $11.068 billion.
Abbott Laboratories said it sees third-quarter adjusted EPS of $1.28 to $1.32, versus estimates of $1.34.
Abbott shares dipped 5.1% to $125.02 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Nuwellis, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares dipped 11.2% to $14.16 in pre-market trading.  Nuwellis shares jumped 131% on Wednesday after the company announced it secured a U.S. patent for an extracorporeal blood filtering machine and methods.</li>
<li>Pitanium Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTNM#NASDAQ">PTNM</a>) declined 7.3% to $12.41 in pre-market trading.</li>
<li>Jade Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBIO#NASDAQ">JBIO</a>) fell 7% to $8.20 in pre-market trading.</li>
<li>MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) dipped 7% to $54.37 in pre-market trading after the company announced a $500 million proposed public offering.</li>
<li>Ingredion Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGR#NYSE">INGR</a>) shares slipped 6.8% to $126.07 in pre-market trading.</li>
<li>Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) declined 5.8% to $12.00 in pre-market trading.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) fell 4.8% to $2.55 in pre-market trading.</li>
</ul>
Now Read This:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46439944/jim-cramer-takes-a-pass-on-this-money-losing-utilities-stock">Jim Cramer &#8216;Takes A Pass&#8217; On This Money-Losing Utilities Stock</a></li>
</ul>
Photo via Shutterstock

INGR

JBIO

NUWE

PTNM

Abbott Laboratories Issues Weak Earnings Forecast, Joins MP Materials And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Abbott Laboratories shares are trading lower after the company issued Q3 adjusted EPS guidance below estimates.

Abbott Laboratories Sees Q3 2025 Adj EPS $1.28-$1.32 vs $1.34 Est

ABBOTT'S FINANCIAL GUIDANCE Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing related sales, to be 7.5% to 8.0%, or 6.0% to 7.0% when including COVID-19 testing-related sales.
Abbott projects full-year 2025 adjusted operating margin to be approximately 23.5% of sales.
Abbott projects full-year 2025 adjusted diluted earnings per share of $5.10 to $5.20 and third-quarter 2025 adjusted diluted earnings per share of $1.28 to $1.32.

Abbott Laboratories Narrows FY2025 Adj EPS Guidance from $5.05-$5.25 to $5.10-$5.20 vs $5.16 Est

Abbott Laboratories Q2 2025 Adj. EPS $1.26 Beats $1.25 Estimate, Sales $11.142B Beat $11.068B Estimate

<h3>Companies Reporting Before The Bell</h3>
• Taiwan Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is estimated to report quarterly earnings at $2.37 per share on revenue of $30.04 billion. 
• Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) is projected to report quarterly earnings at $2.38 per share on revenue of $14.06 billion. 
• Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) is projected to report quarterly earnings at $3.44 per share on revenue of $11.49 billion. 
• GE Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) is likely to report quarterly earnings at $1.41 per share on revenue of $9.57 billion. 
• Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) is likely to report quarterly earnings at $9.19 per share on revenue of $48.21 billion. 
• PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) is expected to report quarterly earnings at $2.03 per share on revenue of $22.33 billion. 
• Insteel Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) is estimated to report quarterly earnings at $0.69 per share on revenue of $176.66 million. 
• Webster Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) is estimated to report quarterly earnings at $1.42 per share on revenue of $712.47 million. 
• Wipro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WIT#NYSE">WIT</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $2.58 billion. 
• Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) is likely to report quarterly earnings at $0.88 per share on revenue of $2.01 billion. 
• U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) is projected to report quarterly earnings at $1.07 per share on revenue of $7.06 billion. 
• Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) is projected to report quarterly earnings at $1.27 per share on revenue of $298.80 million. 
• Snap-on (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) is expected to report quarterly earnings at $4.64 per share on revenue of $1.15 billion. 
• OFG Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OFG#NYSE">OFG</a>) is expected to report quarterly earnings at $1.05 per share on revenue of $181.50 million. 
• Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) is estimated to report quarterly earnings at $2.67 per share on revenue of $6.92 billion. 
• ManpowerGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAN#NYSE">MAN</a>) is expected to report quarterly earnings at $0.69 per share on revenue of $4.35 billion. 
• Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) is expected to report quarterly earnings at $0.87 per share on revenue of $2.22 billion. 
• Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is estimated to report quarterly earnings at $1.07 per share on revenue of $2.63 billion. 
• Bank7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) is projected to report quarterly earnings at $0.99 per share on revenue of $22.87 million. 
• Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) is projected to report quarterly earnings at $1.25 per share on revenue of $11.04 billion. 
<h3>Companies Reporting After The Bell</h3>
• Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) is estimated to report quarterly earnings at $7.06 per share on revenue of $11.05 billion. 
• Interactive Brokers Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) is estimated to report quarterly earnings at $0.45 per share on revenue of $1.37 billion. 
• Western Alliance (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) is estimated to report quarterly earnings at $2.02 per share on revenue of $842.44 million. 
• F N B (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNB#NYSE">FNB</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $422.94 million. 
• Simmons First Ntl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFNC#NASDAQ">SFNC</a>) is likely to report quarterly earnings at $0.40 per share on revenue of $215.64 million. 
• Bank OZK (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OZK#NASDAQ">OZK</a>) is estimated to report quarterly earnings at $1.52 per share on revenue of $421.11 million. 
• Metropolitan Bank Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCB#NYSE">MCB</a>) is estimated to report quarterly earnings at $1.69 per share on revenue of $72.69 million. 
• Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) is expected to report quarterly earnings at $1.21 per share on revenue of $179.61 million. 
• Cohen &amp; Steers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNS#NYSE">CNS</a>) is projected to report quarterly earnings at $0.75 per share on revenue of $135.49 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSVN

FITB

IIIN

INDB

SFNC

TCBI

Earnings Scheduled For July 17, 2025

Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) will release earnings results for the second quarter, before the <a href="https://www.benzinga.com/quote/abt/earnings">opening bell on Thursday, July 17.</a>
Analysts expect the North Chicago, Illinois-based company to report quarterly earnings at $1.25 per share, up from $1.14 per share in the year-ago period. Abbott Laboratories projects to report quarterly revenue at $11.02 billion, compared to $10.38 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 27, Abbott announced the U.S. Food and Drug Administration approved the company&#8217;s Tendyne&#x2122; transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease.
Abbott Laboratories shares rose 0.1% to close at $131.49 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/abt/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Morgan Stanley analyst David Lewis maintained an Equal-Weight rating and raised the price target from $127 to $137 on July 15, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Raymond James analyst Jayson Bedford maintained an Outperform rating and boosted the price target from $132 to $142 on April 17, 2025. This analyst has an accuracy rate of 67%.</li>
<li>Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $158 to $159 on April 17, 2025. This analyst has an accuracy rate of 66%.</li>
<li>Stifel analyst Rick Wise maintained a Buy rating and boosted the price target from $135 to $145 on April 17, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Jefferies analyst Matthew Taylor maintained a Hold rating and increased the price target from $135 to $137 on April 17, 2025. This analyst has an accuracy rate of 69%.</li>
</ul>
Considering buying ABT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/ABT/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="562" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186-1024x562.png" alt="" class="wp-image-987165" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186-1024x562.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186-300x165.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186-768x421.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/16023805/image-186.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46415122/top-2-tech-telecom-stocks-that-may-keep-you-up-at-night-this-month">Top 2 Tech &amp; Telecom Stocks That May Keep You Up At Night This Month</a></li>
</ul>
Photo via Shutterstock

Abbott Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Press Releases

Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes

Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery

Dividends

Abbott Declares 406th Consecutive Quarterly Dividend

Abbott Receives Health Canada Authorization for Whole Blood Rapid Test to Help Assess Suspected Concussions

New Research on Abbott's Healthy Food Rx Program Shows 'Food is Medicine' Approach Helps People Living With Diabetes Eat Better and Feel Healthier

Abbott Hosts Conference Call for Second-Quarter Earnings

Abbott's Latest-Generation FreeStyle Libre 3 Plus Glucose Sensor Technology Launches in Canada

Small Cap

Opinion

Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

Ainnova Tech Reaches Major FDA Milestone in AI-Powered Diabetic Retinopathy Detection

Abbott Reports Second-Quarter 2025 Results

AVAI

DXCM

IRTC

TNDM

Baxter Intl

Becton, Dickinson and Company Common Stock

Becton Dickinson

Boston Scientific Corporation Common Stock

Boston Scientific

DexCom

Edwards Lifesciences Corporation Common Stock

Edwards Lifesciences

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Techs

Glaukos

Globus Medical, Inc. Class A Common Stock

Globus Medical

Hologic

IDEXX Laboratories

iRhythm Technologies, Inc. - Common Stock

iRhythm Technologies

Intuitive Surgical

Integer Holdings Corporation Common Stock

Integer Holdings

Masimo

Medtronic

Penumbra

Koninklijke Philips N.V. NY Registry Shares

Koninklijke Philips

Insulet

ResMed

Smith & Nephew

Steris

Stryker

Teleflex

TransMedics Group

Zimmer Biomet Holdings, Inc. Common Stock

Zimmer Biomet Holdings

Wells Fargo

Raymond James

Mizuho

Jefferies

BTIG

Screenshot 2025-02-24 at 11.35.34 PM

Biotech

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2025-02-24 at 6.22.23 PM

GCTK

Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial

Screenshot 2024-12-03 at 7.43.04 PM

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Comments

Abbott Laboratories

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL